Molecular Hydrogen on the Path to Modern Medicine

by H2 Global Group | Jan 22, 2026 | Health

A global problem without a simple solution

Dementia and neurodegenerative diseases are among the greatest challenges of modern medicine today. They affect tens of millions of people worldwide, and their impact is not only medical but also social and economic. The global cost of caring for patients with dementia amounts to trillions of dollars annually and continues to rise as life expectancy increases.

For this reason, global medicine is increasingly focusing on early stages—phases where it is possible to work with safe, simple, and non-invasive approaches that have the potential to improve quality of life while meeting strict regulatory requirements. MCI represents one of these key intervention points.

Source: https://domaci.hn.cz/c1-67836560-zive-molekularni-vodik-na-ceste-do-moderni-mediciny

The clinical study has been launched

by H2 Global Group | Jan 20, 2026 | Health

Today in Ostrava, the clinical evaluation of the device was officially launched as part of a clinical study aimed at demonstrating the safety of non-invasive inhalation of molecular hydrogen in patients with mild cognitive impairment (MCI), which may precede the development of Alzheimer’s dementia.

The study connects a Czech clinical site with a top-tier Japanese scientific team and represents an important step toward moving molecular hydrogen from the realm of research into legitimate use in healthcare.

The project is led by the Czech company H2 Medical Technologies, part of the H2 Global Group.

We would like to thank all partners and teams who are part of this milestone.

You can find the article here:
https://www.metro.cz/protext/ceska-republika-v-cele-inovaci-dnes-bylo-zahajeno-klinicke-hodnoceni-pristroje-s-molekularnim-vodike.A260119_150700_metro-protext_air

Science That Makes Sense: Molecular Hydrogen as an Investment in Health and the Future

by H2 Global Group | Jan 17, 2026 | Health

PharmDr. Milan Krajíček is a pharmacist and entrepreneur who has spent his entire life combining rigorous expertise, regulatory discipline, and the ability to turn ideas into practice—with a single goal: to ensure that science truly serves people. In the article, he explains why he has devoted years to molecular hydrogen and why he now sees it not as a product, but as a pathway to the medicine of the future, longevity, and measurable impact—as well as an exceptionally attractive opportunity for investors and strategic partners.

You can read the full article here:
https://www.metro.cz/protext/veda-ktera-dava-smysl-molekularni-vodik-jako-investice-do-zdravi-a-budoucnosti.A260116_143100_metro-protext_air

Japanese Professor Shigeo Ohta on Alzheimer’s Dementia: Why We Do What We Do – They Wrote About Us as Well

by H2 Global Group | Jan 14, 2026 | Health

When I look back today, I see more than 21 years of life devoted to a single idea.
The idea that even the smallest element in the universe can have a profound significance for humankind.

Molecular hydrogen has accompanied me throughout most of my scientific career—not as a passing trend or a shortcut to success, but as a long, sometimes lonely journey filled with experiments, doubts, rejections, and quiet discoveries that, at first, were understood by only a handful of people in the world.

…you can find the full article here: https: Japonský profesor Shigeo Ohta na téma Alzheimerova demence: Proč to vlastně všechno děláme

Authority in the Field of Molecular Hydrogen

by H2 Global Group | Jan 13, 2026 | Health

On Friday, we welcomed Professor Shigeo Ohta to the Czech Republic — a world-renowned authority in the field of molecular hydrogen and co-founder of H2 Global Group.

Together with Czech experts, we are officially launching the first clinical study in the Czech Republic focused on the use of molecular hydrogen in patients with mild cognitive impairment (MCI).

🔹 January 19, 2026 – study launch
🔹 January 22, 2026 at 2:00 PM – press conference at ČTK Prague (media and partners welcome)

As Prof. Ohta stated:
“…together with the team in the Czech Republic, we want to change the field so that it has a standardized pathway toward regulatory registration.”

Our goal is clear: to clinically validate, standardize, and advance the technology into the EU regulatory framework, and subsequently open space for international cooperation, clinical partners, and strategic investors.

Full article here: Vědecká autorita z Japonska, profesor Shigeo Ohta, přicestoval do Česka: skupina H2 Global Group spouští v ČR klinickou studii s molekulárním vodíkem – Metro.cz